Novartis Quarterly Financial Results

Q3 2020

Q3 2020 results - Tuesday, October 27, 2020

Media release

English (PDF 0.2 MB)

Deutsch (PDF 0.2 MB)

Français (PDF 0.3 MB)

 

Interim financial report (PDF 0.8 MB)

Watch the webcast

Read the presentation transcript

Download the podcast (MP3 41 MB)

Download the presentation (PDF 2.7 MB)

 

  Continuing operations1
Key figures2 Q3 2020
(USD m)		 Q3 2019
(USD m)		 % change
(USD/cc)
Net sales 12,259 12,172 1 (cc: 0)
Operating income 2,412 2,358 2 (cc: 9)
Net income 1,932 2,041 -5 (cc: 0)
EPS (USD) 0.85 0.90 -6 (cc: 0)
Free cash flow 2,697 3,968 -32

Core		      
Operating income 4,069 3,748 9 (cc: 11)
Net income 3,467 3,212 8 (cc: 10)
EPS (USD) 1.52 1.41 8 (cc: 9)

 

 

 

  1. Refers to continuing operations as defined on page 42 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions.
  2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 54 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Q2 2020

Q2 2020 results - Tuesday, July 21, 2020

Media release

English (PDF 0.2 MB)

Deutsch (PDF 0.2 MB)

Français (PDF 0.3 MB)

Interim financial report (PDF 0.8 MB)

Watch the webcast

Read the presentation transcript

Download the podcast (MP3 44 MB)

Download the presentation (PDF 2.6 MB)

 

  Continuing operations1
Key figures2 Q2 2020
(USD m)		 Q2 2019
(USD m)		 % change
(USD/cc)
Net sales 11,347 11,764 -4 (cc: -1)
Operating income 2,352 2,663 -12 (cc: -4)
Net income 1,867 2,109 -11 (cc: -4)
EPS (USD) 0.82 0.91 -10 (cc: -3)
Free cash flow 3,631 3,612 1

Core		      
Operating income 3,669 3,648 1 (cc: 6)
Net income 3,108 3,096 0 (cc: 5)
EPS (USD) 1.36 1.34 1 (cc: 6)
  1. Refers to continuing operations as defined on page 42 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions
  2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 54 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

XBRL package Q2 2020

Documents Novartis results in XML format in line with requirements of the US Securities and Exchange Commission (SEC).

XBRL Package (ZIP 0.4 MB)

Q1 2020

Q1 2020 results - Tuesday, April 28, 2020

Media release

English (PDF 0.2 MB)

Deutsch (PDF 0.2 MB)

Français (PDF 0.2 MB)

Interim financial report (PDF 0.6 MB)

Watch the webcast

Read the presentation transcript

Download the podcast (MP3 45 MB)

Download the presentation (PDF 3.0 MB)

 

  Continuing operations1
Key figures2 Q1 2020
(USD m)		 Q1 2019
(USD m)		 % change
(USD/cc)
Net sales 12,283 11,106 11 (cc: 13)
Operating income 2,744 2,242 22 (cc: 30)
Net income 2,173 1,868 16 (cc: 24)
EPS (USD) 0.96 0.81 19 (cc: 27)
Free cash flow 2,021 1,869 8

Core		      
Operating income 4,177 3,254 28 (cc: 34)
Net income 3,549 2,811 26 (cc: 31)
EPS (USD) 1.56 1.21 29 (cc: 34)

 

  1. Refers to continuing operations as defined on page 33 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions.
  2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 43 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Annual results and Q4 2019

Annual results and Q4 2019
Wednesday, January 29, 2020

Media release

English (PDF 0.1 MB)

Deutsch (PDF 0.1 MB)

Français (PDF 0.1 MB)

 

Condensed financial report (PDF 0.7 MB)

 

Watch the webcast

Read the presentation transcript

Download the podcast (MP3 43 MB)

Download the presentation (PDF 3.6 MB)

 

Key figures2 Continuing operations1
  Q4 2019
(USD m)		 Q4 2018
(USD m)		 % change
(USD/cc)
Net sales 12,403 11,481 8 (cc: 9)
Operating income 1,823 1,362 34 (cc: 37)
Net income 1,129 1,220 -7 (cc: -6)
EPS (USD) 0.50 0.53 -6 (cc: -4)
Free cash flow 3,488 2,913 20

Core		      
Operating income 3,462 3,112 11 (cc: 13)
Net income 2,985 2,681 11 (cc: 13)
EPS (USD) 1.32 1.16 14 (cc: 15)

 

  1. Refers to continuing operations as defined on page 45 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions.
  2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 58 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Archive

2019 Quarterly Results

Q3 2019 Media Release (PDF 0.1 MB)

Q3 2019 Financial Report (PDF 0.8 MB)

Q2 2019 Media Release (PDF 0.2 MB)

Q2 2019 Financial Report (PDF 0.6 MB)

Q1 2019 Media Release (PDF 0.5 MB)

Q1 2019 Financial Report (PDF 0.5 MB)

2018 Quarterly Results

Q4 2018 Media Release (PDF 0.1 MB)

Q4 2018 Financial Report (PDF 0.6 MB)

Q3 2018 Media Release (PDF 0.1 MB)

Q3 2018 Financial Report (PDF 0.7 MB)

Q2 2018 Media Release (PDF 0.1 MB)

Q2 2018 Financial Report (PDF 0.5 MB)

Q1 2018 Media Release (PDF 0.1 MB)

Q1 2018 Financial Report (PDF 0.5 MB)

2017 Quarterly Results

Q4 2017 Media Release (PDF 0.4 MB)

Q4 2017 Financial Report (PDF 0.5 MB)

Q3 2017 Media Release (PDF 0.1 MB)

Q3 2017 Financial Report (PDF 0.5 MB)

Q2 2017 Media Release (PDF 0.4 MB)

Q2 2017 Financial Report (PDF 0.5 MB)

Q1 2017 Media Release (PDF 0.3 MB)

Q1 2017 Financial Report (PDF 0.4 MB)

2016 Quarterly Results

Q4 2016 Media Release (PDF 0.4 MB)

Q4 2016 Financial Report (PDF 0.5 MB)

Q3 2016 Media Release (PDF 0.1 MB)

Q3 2016 Financial Report (PDF 0.5 MB)

Q2 2016 Media Release (PDF 0.3 MB)

Q2 2016 Financial Report (PDF 0.5 MB)

Q1 2016 Media Release (PDF 0.3 MB)

Q1 2016 Financial Report (PDF 0.4 MB)

2015 Quarterly Results

Q4 2015 Media Release (PDF 0.5 MB)

Q4 2015 Financial Report (PDF 0.6 MB)

Q3 2015 Media Release (PDF 0.5 MB)

Q3 2015 Financial Report (PDF 0.6 MB)

Q2 2015 Media Release (PDF 0.4 MB)

Q2 2015 Financial Report (PDF 0.6 MB)

Q1 2015 Media Release (PDF 0.4 MB)

Q1 2015 Financial Report (PDF 0.5 MB)

Disclaimer: 

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

Related Links

Presentations and Events

View recent presentations and learn more about upcoming events

Visit our Event Calendar
 

Contact Investor Relations

Investors International:
Call +41 61 324 79 44

Investors North America:
Call +1 862 778 5052

Novartis Share Registry:
For information relating to the registration of your shares, including name or address changes, please contact us by e‑mail or telephone:
Call +41 61 324 72 04